New Directions In STD Treatment - University of Hawaii
New Directions In STD Treatment - University of Hawaii New Directions In STD Treatment - University of Hawaii
Gonorrhea – Treatment Issues � Fluoroquinolones NOT recommended for: � Acquisition in CA or Hawaii or other areas with high prevalence of FQ resistance � MSM � Any foreign acquisition- Europe, Middle East, Asia, Pacific � Limited options in cephalosporin allergic patients: � Spectinomycin is no longer manufactured � CDC recommends desensitization* � Could be a special case to consider azithromycin* * Discussed at the 2006 Guidelines Meeting
Gonorrhea Treatment of Urogenital Infections if Fluoroquinolone Resistance Recommended regimens: � Ceftriaxone 125 mg IM x 1* � Cefixime 400 mg PO x 1* Alternative regimens: � Spectinomycin 2 g IM x 1** � Single-dose cephalosporin regimens � Cefpodoxime 400 mg po x 1 � Cefuroxime 1 g po x 1 Azithromycin 2 gm is not recommended by CDC Co-treat for chlamydia unless ruled out by NAAT * suspension may be available ** currently not manufactured *Preferred and only recommended regimen for pharyngeal infection
- Page 1 and 2: New Directions in STD Treatment: Hi
- Page 3 and 4: CDC 2006 STD Treatment Guidelines D
- Page 5 and 6: Challenging Management Dilemmas in
- Page 7 and 8: Sexual History Taking: The 5 P’s
- Page 9 and 10: Recommend Nucleic Acid Amplificatio
- Page 11 and 12: Percent Screened Estimated Chlamydi
- Page 13 and 14: STD Screening for MSM STD Site Type
- Page 15 and 16: Prevalence of rectal chlamydia and
- Page 17 and 18: Prevalence of pharyngeal chlamydia
- Page 19 and 20: C. trachomatis NAAT Testing …not
- Page 21 and 22: Chlamydia Treatment in Pregnancy Re
- Page 23 and 24: Percent 16 14 12 10 Infection Durin
- Page 25 and 26: Provider Barriers to PDPT, CA 2002
- Page 27 and 28: Gonorrhea Screening in Females �
- Page 29: Percent of Neisseria gonorrhoeae Is
- Page 33 and 34: Lymphogranuloma Venereum (LGV) C. t
- Page 35 and 36: LGV Proctocolitis: Serologic Diagno
- Page 37 and 38: Phil and the Penis on the Go
- Page 39 and 40: The Three “R”s of Syphilis �
- Page 41 and 42: Latent Syphilis � No clinical man
- Page 43 and 44: Syphilis EIA Tests �Treponemal te
- Page 45 and 46: Criteria for CSF Examination � Ne
- Page 47 and 48: Syphilis Resistant to Azithromycin!
- Page 51 and 52: HSV Issues � Role of type-specifi
- Page 53 and 54: Rates of Transmission of HSV-2 to S
- Page 55 and 56: Genital Herpes - Treatment Issues
- Page 57 and 58: HPV Issues � Clarify uses of HPV
- Page 59 and 60: Issues Regarding Anal Cancer Screen
- Page 61 and 62: Cervicitis - Diagnostic Issues �
- Page 63 and 64: Pelvic Inflammatory Disease Issues
- Page 65 and 66: PID: Oral Treatment Regimens Oral r
- Page 67 and 68: Vaginitis Trichomonas Bacterial Vag
- Page 69 and 70: Tinidazole: A New Treatment Option
- Page 71 and 72: Proposed Management Trichomoniasis
- Page 73 and 74: BV Treatment Recommended regimens:
- Page 75: STD Resources California STD/HIV Pr
Gonorrhea <strong>Treatment</strong> <strong>of</strong> Urogenital<br />
<strong>In</strong>fections if Fluoroquinolone Resistance<br />
Recommended regimens:<br />
� Ceftriaxone 125 mg IM x 1*<br />
� Cefixime 400 mg PO x 1*<br />
Alternative regimens:<br />
� Spectinomycin 2 g IM x 1**<br />
� Single-dose cephalosporin regimens<br />
� Cefpodoxime 400 mg po x 1<br />
� Cefuroxime 1 g po x 1<br />
Azithromycin 2 gm is not recommended by CDC<br />
Co-treat for chlamydia unless ruled out by NAAT<br />
* suspension may be available<br />
** currently not manufactured<br />
*Preferred and only recommended<br />
regimen for pharyngeal infection
Change language